医療従事者の為の最新医療ニュースや様々な情報・ツールを提供する医療総合サイト

TOKYO

Sosei Group Corporation (TOKYO:4565), the biopharmaceutical company, today announces that its Japanese subsidiary, Sosei Co., Ltd., (“Sosei K.K.”) has signed a distribution agreement for commercialization of SO-1105 in Japan with FUJIFILM Pharma Co., Ltd (“FUJIFILM Pharma”).

SO-1105 is an antifungal agent, administered as a muco-adhesive buccal tablet for the treatment of oropharyngeal candidiasis in immunocompromised patients. It has the potential to become the first long-acting, sustained-release treatment in tablet form for oropharyngeal candidiasis in Japan that could enhance patients’ compliance and quality of life.

SO-1105 was originally developed by a French pharmaceutical company, BioAlliance Pharma, which received its first marketing authorization for SO-1105 in France in October 2006. SO-1105 has since been registered in 24 European countries, in South Korea, and in the United States, under the trade names Loramyc®/Oravig®. Sosei K.K. acquired exclusive development and commercialization rights in Japan from BioAlliance in May 2011.

Under the terms of the agreement with FUJIFILM Pharma, Sosei K.K. will be responsible for registration, manufacturing and supply, and FUJIFILM Pharma for marketing and distribution of SO-1105. Based on this agreement, Sosei K.K. is entitled to receive a total of 900 million yen for key initial payment and achieved development and regulatory milestones, as well as margin on the sales of SO-1105 to FUJIFILM Pharma. Additional payments may also be received upon achievement of sales-based milestones.

We believe that the distribution agreement with FUJIFILM Pharma, which has expertise in infectious diseases, will help us expand the reach of SO-1105 to more oropharyngeal candidiasis patients.

– Ends –

About Oropharyngeal Candidiasis

Fungal infections of the oral mucosa are most frequently caused by Candida species, with C. albicans being the most common species associated with such infections. Oropharyngeal candidiasis is commonly found in immuno-compromised patients, including HIV and cancer patients, and in other chronic disease states such as diabetes. For instance, oropharyngeal candidiasis is the most frequently occurring infection in head and neck cancer patients undergoing radiation therapy. The clinical presentation of oropharyngeal candidiasis is variable with symptoms including soreness, burning, and/or altered taste. The signs of clinical candidiasis usually include white pseudomembraneous plaques and patches (thrush), erythematous lesions or occasionally angular cheilitis. Left untreated, the condition may progress to involve the esophagus or to more serious systemic complications.

About Sosei Group Corporation

Sosei is an international biopharmaceutical company anchored in Japan with a global reach. It practises a reduced risk business model by acquiring compounds from, and bringing compounds into, Japan through exploitation of its unique position within global markets.
For further information about Sosei, please visit www.sosei.com.

About FUJIFILM Pharma

FUJIFILM Pharma Co., Ltd. started business in April 2010, aiming to help enhance people’s quality of life by development and sales of ethical pharmaceutical products of Fujifilm group.
FUJIFILM Pharma Co., Ltd. is enhancing the sales platform especially of drugs for diseases such as diabetes and infectious diseases and is also further strengthening the structure for providing information about pharmaceutical products.
For more information, please refer to our website: http://ffp.fujifilm.co.jp

About BioAlliance Pharma

Dedicated to cancer and supportive care – cancer related pathologies, chemotherapy and radiotherapy-induced complications and opportunistic infections in immunocompromised patients – BioAlliance conceives and develops innovative products, especially in the hospital setting and for orphan or rare diseases.
For more information, visit the BioAlliance Pharma web site at www.bioalliancepharma.com.